We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Cell Genesys has announced the final results of its second multicenter, Phase II trial of GVAX immunotherapy for prostate cancer, which evaluated escalating doses of the immunotherapy in 80 patients with metastatic hormone-refractory prostate cancer.
Sciele Pharma announced that it has begun enrolling patients in a pivotal Phase III safety trial utilizing glycopyrrolate to treat chronic, moderate-to-severe drooling in pediatric patients.
Icagen announced that, following a planned meeting of the independent data monitoring committee (DMC) for the company's Phase III ASSERT trial of senicapoc for the treatment of sickle cell disease in adults, the DMC recommended that the trial be terminated because of the low probability of achieving a reduction in crisis rate, the primary endpoint.
Eurand has released data from two Phase III clinical trials of its lead product candidate, Zentase, for the treatment of exocrine pancreatic insufficiency (EPI).
Impax Laboratories announced that the FDA has granted final approval to its abbreviated new drug applications for generic Corzide 40 mg/5 mg and 80 mg/5 mg.
Novavax's virus-like particle (VLP) vaccine triggered a robust immune response and provided protection against the H9N2 strain of avian influenza, according to preclinical data published in the online edition of the journal Vaccine.
Biota recently announced the successful completion of the second stage of its Phase I safety and tolerability study of BTA798, a potent inhibitor of human rhinovirus (HRV), the major cause of the common cold.